| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 73.14 | 6.7% |
| Total Income | 73.14 | 6.7% |
| Expenditure | 55.75 | 9.8% |
| PBT | -10.42 | 44.6% |
| Net Profit | -10.67 | 43.5% |
| OPM | -9.36% | 12.78pp |
| NPM | -14.60% | 12.98pp |
| EPS | -0.16 | 46.7% |
Evolus Reports Q1 2026: Revenue $73.1 Million, Up 7% YoY
05 May 2026 · 5 May, 1:43 am
Summary
Evolus, Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a 7% increase in total net revenues to $73.1 million. The company achieved positive adjusted EBITDA for the second consecutive quarter, amounting to $0.6 million. Evolus reaffirmed its full-year 2026 net revenue guidance of $327 million to $337 million and expects a low- to mid-single digit adjusted EBITDA margin. Management highlighted the continued strength of the business and the benefits from structural improvements implemented in 2025.
Key Highlights
- 1
Evolus reported global net revenue of $73.1 million for the first quarter of 2026, an increase of 7% over the prior year.
- 2
The company achieved a GAAP operating loss of $6.8 million and an adjusted EBITDA of $0.6 million for the first quarter of 2026.
- 3
Evolus reaffirmed its full-year 2026 net revenue guidance of $327 million to $337 million.
- 4
The company expects to achieve a low- to mid-single digit adjusted EBITDA margin in 2026.
- 5
Total purchasing accounts increased by nearly 500 in the first quarter, with more than 18,100 customers having purchased from Evolus since launch.
- 6
Members in the Evolus Rewards™ consumer loyalty program grew by nearly 75,000 during the quarter to approach 1.5 million, representing a 27% increase compared to Q1 2025.
Management Comments
David Moatazedi
“We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability1 in what is seasonally our lowest revenue quarter. This performance reflects continued strength of the business and the benefit from structural improvements we implemented in 2025. Importantly, achieving profitability1 in the first quarter further reinforces the durability of our operating model and our confidence in achieving full-year profitability1 in 2026.” “Underlying demand across the business remains healthy and consistent with the momentum we exited 2025. In the first quarter, we delivered unit growth for Jeuveau® across both U.S. and International markets, and during the second quarter of 2026 we expect to overcome some unique dynamics from the prior year, resulting in high single-digit Jeuveau® growth in the first half and supporting double-digit total revenue growth for the full year. Our performance continues to be supported by strong engagement from our existing customer base, expansion across national accounts, and ongoing growth in our international markets. At the same time, Evolysse® is building momentum and contributing to our expanding share of wallet within accounts.” “We are continuing to advance our strategy of building a global performance beauty company supported by a differentiated and expanding portfolio. Our commercial platform continues to scale effectively, supported by strong growth in Evolus Rewards™, which now approaches 1.5 million members, along with increasing customer penetration and consistent repeat utilization. We are also progressing key milestones, including the upcoming launch in mid-May of all four injectable hyaluronic acid gels under the Estyme® brand in Europe, and we continue to anticipate U.S. approval of Evolysse® Sculpt later this year. With a more efficient cost structure and expanding operating leverage, we reiterate our full‑year guidance to deliver positive Adjusted EBITDA and double‑digit revenue growth in 2026, while continuing to invest in long‑term value creation.”
Informational and educational content only. Not investment advice.